Real World Study of Linperlisib for Lymphoma Treatment
NCT05863871 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2023-05-18
Summary
This is a multicenter, non-interventional and observational real-world study to evaluate the efficacy and safety of linperlisib in patients with lymphoma.
Conditions
- Focus on the Lymphoma Including B/T-cell Lymphoma
Interventions
- DRUG
-
Linperlisib
80 mg, qd
Sponsors & Collaborators
-
Tianjin Medical University Cancer Institute and Hospital
collaborator OTHER -
Ruijin Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-05-31
- Primary Completion
- 2027-06-30
- Completion
- 2027-06-30
Countries
- China
Study Locations
More Related Trials
-
A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL
NCT06981988 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL
NCT05883709 ·Status: UNKNOWN
-
Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
NCT07139353 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)
NCT06712173 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Linperlisib-based Treatment Regimen in Newly Diagnosed Nodal T-follicular Helper Cell Lymphoma (nTFHL)
NCT06347653 ·Status: RECRUITING ·Phase: PHASE2
-
The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
NCT06656234 ·Status: NOT_YET_RECRUITING
-
A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma
NCT06548347 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study
NCT07240194 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
NCT05846750 ·Status: RECRUITING ·Phase: PHASE2
-
Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
NCT04023916 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
NCT07189065 ·Status: RECRUITING ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05875428 ·Status: UNKNOWN ·Phase: PHASE2
-
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
NCT05575973 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
NCT05267054 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL
NCT04361279 ·Status: COMPLETED ·Phase: PHASE3
-
Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma
NCT05949944 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
NCT05899621 ·Status: RECRUITING
-
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
NCT05182957 ·Status: RECRUITING ·Phase: PHASE2
-
PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT
NCT04799314 ·Status: UNKNOWN ·Phase: PHASE3
-
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
NCT05557903 ·Status: UNKNOWN ·Phase: PHASE1
-
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
NCT05846763 ·Status: RECRUITING
-
An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT06693973 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
NCT05990985 ·Status: NOT_YET_RECRUITING ·Phase: NA